P267 Validation of the short inflammatory bowel disease questionnaire as an outcome measure in Crohn’s disease patients
S. Reggev1, G. Goran1, O. Sarid1, D. Schwartz2, R. Sergienko3, V. Slonim-Nevo1, M. Friger3, A. Nemirovsky4, E. Vinogradov4, A. Monsonego4, D. Greenberg5, S. Odes6
1Ben-Gurion University of the Negev, Social Work, Beer Sheva, Israel, 2Soroka Medical center, Gastroenterology, Beer Sheva, Israel, 3Ben-Gurion University of the Negev, Public Health, Beer Sheva, Israel, 4Ben-Gurion University of the Negev, Microbiology and Immunology, Beer Sheva, Israel, 5Ben-Gurion University of the Negev, Health Systems Management, Beer Sheva, Israel, 6Ben-Gurion University of the Negev, Health Sciences, Metar, Israel
Health-related quality-of-life by the self-report, disease-specific Short Inflammatory Bowel Disease Questionnaire (SIBDQ) is increasingly used as an outcome measure in Crohn`s disease (CD) patients in clinical trials. Higher SIBDQ scores indicate better quality-of-life; the range is 10 to 70. However, the construct validity of SIBDQ and its responsiveness to change of disease status require validation.
Adult (≥18 years) CD patients (
Demographic and medical characteristics (median, %) of the cohort were: age 30 years; females 65%, married/partner 48%; higher education 83%; BMI 22; non-smokers/past-smokers 92%; disease duration 5 years; past Crohn’s disease-related surgery 17%; Montreal classification A2 89%, L2+L3 89%, B1+B2 89%, perianal disease 18%; medications: corticosteroids 4%, 5-ASA 5%, immunomodulators 21%, biologicals 43%. HBI and SIBDQ median scores at T1 and T2 were: HBI: 9 and 4 (
The SIBDQ measure is a valid assessment of quality-of-life in CD, correlating with biomarkers and sensitive to change of disease activity, with potential for use as a patient-reported outcome in both clinical practice and as a primary end-point in clinical trials.